| abstract |
The application relates to a compound, or an enantiomer, stereoisomer, rotamer, tautomer, racemate, or prodrug of the compound, or a pharmaceutically acceptable salt or solvate of the compound or the prodrug. Is disclosed. This compound has the general structure shown in Formula 1 and pharmaceutically acceptable salts, solvates or esters thereof. Also disclosed are methods of treating diseases mediated by chemokines, such as palliative treatment, curative treatment, prophylactic treatment using compounds of Formula 1 for certain diseases and conditions, for example. Diseases and conditions include, for example, inflammatory disease, autoimmune disease, transplant rejection, infectious disease, fixed drug eruption, delayed type hypersensitivity response of the skin, eye inflammation, type I diabetes, viral meningitis and tumor It is. |